Mark Flynn
Investor Relations
Good morning, everyone, and thank you again for joining us today. My name is Mark Flynn from the Investor Relations at Nova Eye Medical Limited. Today’s session is an investor briefing, but just a brief reminder, we will include some forward-looking statements. Actual outcomes may differ due to risks and uncertainties, but please refer to the disclaimer in the presentation.
Format is straightforward as usual. Tom will first walk through a short presentation. After that, I’ll ask a number of questions received from investors. [Operator Instructions] With that, I’ll hand over to Managing Director, Tom Spurling.
Thomas Spurling
MD & Executive Director
Thanks, Mark, and thanks, everyone, for joining us today. We’ve got a good turnout. And for those long-time listeners, long-term listeners, some repeating of the message, but I find that, that will help out — help get more people understanding our story if you hear it all the once and for those new ones. So thank you. Bear with me.
Glaucoma is about the buildup of pressure, a failure of plumbing. Building up of pressure can lead to crushing of the optic nerve and blindness. It’s a big market.
Next slide, Mark. We describe our market here, 84 million. We’re a subset of pharmaceuticals, maybe $4.3 billion of drugs being used eye drops. We participate in what we call the interventional glaucoma segment, which were early surgical engagement to change disease trajectory using devices. This is important so that patients end up with a low quality of life, having to take drops every day and are often don’t comply properly. So the disease is not managed easily with drops. A surgical intervention to get people off drops
#Nova #Eye #Medical #Limited #ELXMF #Earnings #Call #Transcript